|In vitro (25°C)||DMSO||22 mg/mL (44.57 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||<1 mg/mL (<1 mM)|
|In vivo||0.5% CMC||6 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||20.26 mL||101.3 mL||202.59 mL|
|0.5 mM||4.05 mL||20.26 mL||40.52 mL|
|1 mM||2.03 mL||10.13 mL||20.26 mL|
|5 mM||0.41 mL||2.03 mL||4.05 mL|
*The above data is based on the productmolecular weight 493.6 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
SU10944 is a small molecule kinase inhibitor of VEGFR that inhibits neovascularization and permeability, and is distributed to the eye upon …
Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9…
Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial c…
Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived …
Motesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), an…
Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.